Adenoma clinical trials at UCSF
1 research study open to eligible people
Showing trials for
VT3989 in Patients With Metastatic Solid Tumors
open to eligible people ages 18 years and up
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
San Francisco, California and other locations
Our lead scientists for Adenoma research studies include Varun Monga.
Last updated: